First in Man Evaluation of the Safety and Potential Efficacy of TOL101 Induction to Prevent Kidney Transplant Rejection

被引：0
|
作者：
Flechner, S. M. [1 ]
Mulgaonkar, S. [2 ]
Melton, L. [3 ]
Wiseman, A. [4 ]
Sung, R. [5 ]
Waid, T. [6 ]
Shihab, F. [7 ]
Agarwal, A. [8 ]
Getts, Tegaue M. [9 ]
Getts, D. R. [9 ,10 ]
机构：
[1] Cleveland Clin, Cleveland, OH 44106 USA
[2] St Barnabas Hosp, Livingston, NJ USA
[3] Baylor Univ, Med Ctr, Dallas, TX USA
[4] Univ Colorado, Denver, CO 80202 USA
[5] Univ Michigan, Ann Arbor, MI 48109 USA
[6] Univ Kentucky, Lexington, KY USA
[7] Univ Utah, Salt Lak City, UT USA
[8] Univ Virginia, Charlottesville, VA USA
[9] Tolera Therapeut Inc, Kalamazoo, MI USA
[10] Northwestern Univ, Chicago, IL 60611 USA
来源：
TRANSPLANTATION | 2012年 / 94卷 / 10期
关键词：
D O I：
10.1097/00007890-201211271-00188
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
434
引用
收藏
页码：102 / 102
页数：1
相关论文
共 50 条
  • [1] First in Man Evaluation of the Safety and Potential Efficacy of TOL101 Induction To Prevent Kidney Transplant Rejection.
    Flechner, S. M.
    Mulgaonkar, S.
    Melton, L.
    Wiseman, A.
    Sung, R.
    Waid, T.
    Shihab, F.
    Getts, M. T.
    Getts, D. R.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 : 55 - 55
  • [2] First-in-Human Study of the Safety and Efficacy of TOL101 Induction to Prevent Kidney Transplant Rejection
    Flechner, S. M.
    Mulgoankar, S.
    Melton, L. B.
    Waid, T. H.
    Agarwal, A.
    Miller, S. D.
    Fokta, F.
    Getts, M. T.
    Frederick, T. J.
    Herrman, J. J.
    Puisis, J. P.
    O'Toole, L.
    Sung, R.
    Shihab, F.
    Wiseman, A. C.
    Getts, D. R.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 (06) : 1346 - 1355
  • [3] EVALUATING SAFETY AND EFFICACY OF TOL101 INDUCTION TO PREVENT KIDNEY TRANSPLANT REJECTION, PART A INTERIM ANALYSIS
    Getts, Daniel R.
    Wiseman, Alexander C.
    Mulgaonkar, Shamkant
    Sung, Randall S.
    Melton, Larry B.
    Waid, Thomas H.
    Thompson, John S.
    Brown, Stephen A.
    Getts, Meghann T.
    Frederick, Terra J.
    Flechner, Stuart M.
    TRANSPLANT INTERNATIONAL, 2011, 24 : 93 - 93
  • [4] TOL101; a New Aid To Prevent Allograft Rejection.
    Getts, Daniel R.
    Brown, Stephen
    Siemionow, Maria
    Miller, Stephen D.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 : 728 - 729
  • [5] Initial Phase 2 Safety, Efficacy, and Pharmacokinetic Study of TOL-101 for Induction Therapy in Kidney Transplantation.
    Flechner, S.
    Mulgoankar, S.
    Melton, L.
    Waid, T.
    Agarwal, A.
    Shihab, F.
    Wiseman, A.
    Getts, D.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 89 - 89
  • [6] Initial Phase 2 Safety, Efficacy, and Pharmacokinetic Study of TOL-101 for Induction Therapy in Kidney Transplantation.
    Flechner, S.
    Mulgoankar, S.
    Melton, L.
    Waid, T.
    Agarwal, A.
    Shihab, F.
    Wiseman, A.
    Getts, D.
    TRANSPLANTATION, 2014, 98 : 89 - 89
  • [7] First Patient Receives Cell Therapy to Prevent Kidney Transplant Rejection
    Philippidis A.
    Genetic Engineering and Biotechnology News, 2022, 42 (06): : 10 - 11
  • [8] Safety and efficacy of basiliximab for the prevention of acute rejection in kidney transplant recipients
    Shah, MH
    Bokhari, MZM
    Bokhari, MTM
    Farooq, A
    Yousaf, SM
    TRANSPLANTATION PROCEEDINGS, 2003, 35 (07) : 2737 - 2738
  • [9] Results of a Phase 2 Safety, Efficacy, and Pharmacokinetic Study of TOL-101, an Anti-TCR Monoclonal Antibody for the Prophylaxis of Acute Rejection in Kidney Transplantation
    Flechner, S.
    Mulgaonkar, S.
    Melton, L.
    Waid, T.
    Sung, R.
    Shihab, F.
    Wiseman, A.
    Getts, D.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 80 - 80
  • [10] Efficacy and Safety of Acute Antibody Rejection Treatment in Pediatric Kidney Transplant Recipients.
    Kincaide, E.
    Hitchman, K.
    Hall, R.
    Yamaguchi, I.
    Crowther, B.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 715 - 715
12345